Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On March 31, 2017, Heat Biologics, Inc., a Delaware corporation,
(the Registrant) issued the attached press release that included
financial information for its fiscal year ended December 31,
2016. A copy of the press release is attached as Exhibit 99.1 to
this Report on Form 8-K. The information contained in the press
release is being furnished to the Commission and shall not be
deemed incorporated by reference into any of the Registrants
registration statements or other filings with the Commission.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
|
99.1 |
Press Release issued by Heat Biologics, Inc. dated March |
|
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC. Heat Biologics, Inc. (NASDAQ:HTBX) Recent Trading Information
Heat Biologics, Inc. (NASDAQ:HTBX) closed its last trading session down -0.001 at 0.870 with 387,204 shares trading hands.
